Shares of Tempus AI (NASDAQ: TEM) skyrocketed 6.65% in Monday's trading session, fueled by the company's announcement of its first whole-genome sequencing test, xH, aimed at advancing personalized cancer treatment and precision medicine.
The Chicago-based AI healthcare technology firm revealed that xH, which is currently available for research use only, will facilitate comprehensive genomic profiling and detection of clinically-relevant variants across hematological cancers like leukemia and lymphoma. With plans for clinical availability within the next year, the test marks Tempus AI's foray into whole-genome sequencing, a platform with the potential to consolidate multiple tests into a single assay and enhance personalized therapy decisions.
In a pilot study, the xH assay demonstrated high sensitivity and concordance with traditional molecular methods, bolstering its promise as a cost-effective, comprehensive tool for genomic profiling in blood cancers. However, despite the promising growth prospects, a Bank of America Securities analyst report maintained a "Hold" rating on Tempus AI, citing a need to balance the company's potential with current performance shortfalls.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.